The room then grew quiet as each stood and recited what he regarded as the “untruths” in his own faith. The minister said that one “untruth” for him was that “Christianity is the only way to God.” The rabbi said for him it was the notion of Jews as “the chosen people.” And the sheik said for him it was the “sword verses” in the Koran, like “kill the unbeliever.”

“It is a verse taken out of context,” Sheik Rahman said, pointing out that the previous verse says that God has no love for aggressors. “But we have to acknowledge that ‘kill the unbelievers’ is an awkward verse,’ ” the sheik said as the crowd laughed. “Some verses are literal, some are metaphorical, but the Koran doesn’t say which is which.”

But this latest French utopia has met a prosaic reality: Many of the specially designed bikes, which cost $3,500 each, are showing up on black markets in Eastern Europe and northern Africa. Many others are being spirited away for urban joy rides, then ditched by roadsides, their wheels bent and tires stripped.

With 80 percent of the initial 20,600 bicycles stolen or damaged, the program’s organizers have had to hire several hundred people just to fix them. And along with the dent in the city-subsidized budget has been a blow to the Parisian psyche.

There are roughly three New Yorks. There is, first, the New York of the man or woman who was born here, who takes the city for granted and accepts its size and turbulence as natural and inevitable. Second, there is the New York of the commuter—the city that is devoured by locusts each day and spat out each night. Third, there is the New York of the person who was born somewhere else and came to New York in quest of something. Of these three trembling cities the greatest is the last—the city of final destination, the city that is a goal. It is this third city that accounts for New York’s high-strung disposition, its poetical deportment, its dedication to the arts, and its incomparable achievements. Commuters give the city its tidal restlessness; natives give it solidity and continuity; but the settlers give it passion. And whether it is a farmer arriving from Italy to set up a small grocery store in a slum, or a young girl arriving from a small town in Mississippi to escape the indignity of being observed by her neighbors, or a boy arriving from the Corn Belt with a manuscript in his suitcase and a pain in his heart, it makes no difference: each embraces New York with the intense excitement of first love, each absorbs New York with the fresh eyes of an adventurer, each generates heat and light to dwarf the Consolidated Edison Company.

Was it true that the president had refused to meet the Dalai Lama on his visit to Washington?

He was told that Obama had indeed tried to curry favor with China by declining to see the Dalai Lama until after the president’s visit to China next month.

Dissing the Dalai was part of a broader new Obama policy called “strategic reassurance” — softening criticism of China’s human rights record and financial policies to calm its fears that America is trying to contain it. (Not to mention our own fears that the Chinese will quit bankrolling our debt.)

The question for India, Kashmiris say, is whether the huge security presence is doing more harm than good. “Maybe at some point in time when the militants were in the thousands it made sense to have so many soldiers here,” said Mehbooba Mufti, leader of a major opposition party here. “But at this point they are not helping in any way. Their mere presence has become a source of friction.

Restarting the War on Cancer has to start at the top: in 1971, Congress decided that the president, not the head of the National Institutes of Health, should appoint the director of the National Cancer Institute. Yet like all too many outposts of the White House, the institute has become a largely rudderless ship in dire need of a bold captain who will settle only for total victory. President Obama must choose strong new leadership for the institute from among our nation’s best cancer researchers; it also needs a seasoned developer of new pharmaceuticals who can radically speed up the pace at which anticancer drugs are developed and clinically tested.